Miniatura

Fitxers

672796.pdf (559.6 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2016-11-01

Llicència de publicació

cc-by-nc-nd (c) Laguno Centeno, Montserrat et. al, 2016
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/160558

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ijid.2016.10.028

Resum

Introduction Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet.

Matèries

Hepatitis C, Interferó, Espanya

Matèries (anglès)

Hepatitis C, Interferon, Spain

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

LAGUNO CENTENO, Montserrat, VON WICHMANN, M. a., VAN DEN EYNDE, Eva, NAVARRO, J., CIFUENTES, Carmen, MURILLAS ANGOITI, Javier, VELOSO, Sergi, MARTÍNEZ REBOLLAR, María, GUARDIOLA, J. m., JOU, A., GÓMEZ-SIRVENT, J. l., CERVANTES, M., PINEDA, J. a., LÓPEZ-CALVO, S., CARRERO, A., MONTES, María luisa, DEIG, E., TAPIZ, A., RUIZ-MESA, J. d, CRUCETA, Anna, DE LAZZARI, E., MALLOLAS MASFERRER, Josep. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. _International Journal Of Infectious Diseases_. 2016. Vol. 53, núm. 46-51. [consulta: 20 de gener de 2026]. ISSN: 1201-9712. [Disponible a: https://hdl.handle.net/2445/160558]

Exportar metadades

JSON - METS

Compartir registre